Background: Early in December 2019, a novel coronavirus, named SARS-CoV-2, caused an outbreak of respiratory disease named COVID-19. The COVID-19 disease has led to severe pneumonia, multiorgan failure, and death. Methods: A detailed literature survey was performed using various databases. Results: Lopinavir/Ritonavir is an orally administrable drug, and after its administration, the viral load is being tested. On the other end, remdesivir even at a very low micromolar concentration blocked the viral infection. Ribavirin combination with Lopinavir/ Ritonavir was intravenously infused for not more than 10 days. The presence or absence of viral load was determined to be the endpoint. Gastrointestinal adverse events were more common in the lopinavir-ritonavir administered patients. Lopinavir-ritonavir treatment was stopped early in patients because of adverse events. Hypertransaminasemia and acute kidney injury were also the most frequent severe adverse events observed. Remdesivir benefited patients with SARS-CoV-2 pneumonia hospitalized outside ICU where the clinical outcome was better and adverse events are less frequently observed. Ribavirin combination with Lopinavir/ Ritonavir was intravenously infused for not more than 10 days and was found to be less effective. Conclusion: The antiviral drugs involved in the treatment of COVID 19 are Lopinavir/Ritonavir, Remdesivir, and Ribavirin. Among which Remdesivir was found to be more effective against COVID 19 with 30% speedy recovery. However, prevention is always better than cure, the prevention methods involve Hand sanitization, gloves, masks, protective suits, social distancing, and self-isolation.